We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-7.6%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.27B
AUM Growth
-$1.19B
Cap. Flow
-$465M
Cap. Flow %
-8.83%
Top 10 Hldgs %
38.7%
Holding
148
New
20
Increased
18
Reduced
35
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$175M
2
HUM icon
Humana
HUM
+$51M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$50.2M
4
BLU
BELLUS Health Inc.
BLU
+$49.6M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$41M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$66.7M
2
BSX icon
Boston Scientific
BSX
+$62.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$61M
4
MRK icon
Merck
MRK
+$51.7M
5
ILMN icon
Illumina
ILMN
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XTNT icon
51
Xtant Medical Holdings
XTNT
$59.1M
$26.1M 0.5%
9,207,012
– –
IQV icon
52
IQVIA
IQV
$40.6B
$26.1M 0.5%
+175,000
New +$27.2M
ONCE
53
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$23.8M 0.45%
244,900
+25,000
+11% +$2.5M
PRTA icon
54
Prothena Corp
PRTA
$444M
$23.7M 0.45%
3,022,117
-43,161
-1% -$383K
AMGN icon
55
Amgen
AMGN
$212B
$23.6M 0.45%
122,100
– –
SYRE icon
56
Spyre Therapeutics
SYRE
$8.32B
$22M 0.42%
114,621
+28,000
+32% +$5.45M
ADVM
57
DELISTED
Adverum Biotechnologies
ADVM
$21.9M 0.42%
401,297
+205,277
+105% +$23.1M
VRCA icon
58
Verrica Pharmaceuticals
VRCA
$92.9M
$21.8M 0.41%
147,973
– –
OBSV
59
DELISTED
ObsEva SA Ordinary Shares
OBSV
$21.7M 0.41%
2,605,531
– –
CRSP icon
60
CRISPR Therapeutics
CRSP
$4.66B
$21.2M 0.4%
+516,400
New +$24.7M
KRYS icon
61
Krystal Biotech
KRYS
$10.7B
$20.9M 0.4%
601,950
-40,056
-6% -$1.79M
GILD icon
62
Gilead Sciences
GILD
$166B
$20.7M 0.39%
326,100
-75,500
-19% -$4.94M
ALC icon
63
Alcon
ALC
$34B
$20.5M 0.39%
351,380
– –
CRVS icon
64
Corvus Pharmaceuticals
CRVS
$1.1B
$20.4M 0.39%
6,767,584
+201,899
+3% +$847K
SCPH
65
DELISTED
scPharmaceuticals
SCPH
$20M 0.38%
3,409,865
– –
IBB icon
66
PUT
iShares Biotechnology ETF
IBB
$9.51B
$19.9M 0.38%
+200,000
New +$20.9M
AUPH icon
67
Aurinia Pharmaceuticals
AUPH
$1.92B
$18.9M 0.36%
3,531,002
– –
NVO
68
Novo Nordisk
NVO
$228B
$17.1M 0.32%
660,000
– –
ZLAB icon
69
Zai Lab
ZLAB
$2.06B
$16.6M 0.32%
514,000
-655,000
-56% -$22.5M
SVA
70
DELISTED
Sinovac Biotech, Ltd
SVA
$16.6M 0.32%
2,839,500
– –
APLS
71
DELISTED
Apellis Pharmaceuticals
APLS
$15M 0.29%
623,859
-1,199,841
-66% -$33M
FOMX
72
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.6M 0.28%
4,788,896
-406,434
-8% -$1.14M
ALPN
73
DELISTED
Alpine Immune Sciences Inc
ALPN
$14.5M 0.28%
3,670,955
– –
KALA icon
74
KALA BIO
KALA
$12M
$13.1M 0.25%
1,381
– –
TAK icon
75
Takeda Pharmaceutical
TAK
$56.6B
$12.9M 0.24%
750,000
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2019 Portfolio in Review

As of Q3 2019, OrbiMed held 148 positions worth $5.27B, down 18% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $465M in Q3 2019, closing 32 positions and reducing 35 holdings. Its most notable exit was Agilent Technologies, an estimated $66.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in SpringWorks Therapeutics worth $161M.

  • OrbiMed's largest Q3 2019 buy was SpringWorks Therapeutics: 7,406,307 shares worth $161M.
  • OrbiMed added most to Ultragenyx Pharmaceutical in Q3 2019, an estimated $41M increase.
  • OrbiMed's biggest Q3 2019 reduction was Boston Scientific, cutting an estimated $62.9M.
  • OrbiMed fully exited Agilent Technologies in Q3 2019, selling an estimated $66.7M.
  • OrbiMed's ten largest holdings make up 39% of its $5.27B portfolio in Q3 2019.
  • OrbiMed opened 20 new positions and closed 32 in Q3 2019.
  • OrbiMed's portfolio value fell 18% quarter-over-quarter to $5.27B.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.